The latest announcement is out from IG Design ( (GB:IGR) ).

Norcros plc announced an Investor Presentation Webinar to discuss its Interim Results for the 27 weeks ending 5th October 2025. The event, led by CEO Thomas Willcocks and CFO James Eyre, is open to ...

Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop ...

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients ...

AMD CEO and Chairman Dr. Lisa Su updated the size of the total addressable market for the AI data center and now sees it ...

Q3 2025 Earnings Call November 12, 2025 7:30 AM ESTCompany ParticipantsSean Washchuk - Senior VP & CFOGeoffrey Martin ...

Over 100 patients treated with AlloNK across autoimmune and oncology indications Refractory rheumatoid arthritis (RA) prioritized as lead indication following FDA Fast Track Designation for AlloNK®, ...

Post-Quantum Cryptography Leadership -- Management highlighted a second major design win with a 'tech giant' involving ...

The Committee of the Whole recommended the Common Council approve the marina contract with Edgewater Resources.

During the third quarter of 2025 we continued strong execution of our financial strategy, resulting in improved equity, lower leverage and extended cash runway. Our cash runway has now been extended ...

Forward-Looking Statements Looking ahead, AltaGas provided financial guidance for 2025, projecting normalized EBITDA between $1,775 million and $1,875 million, compared to $1,769 million in 2024.

Quarterly Performance Highlights Tecnicas Reunidas delivered impressive financial results for Q2 2025, with sales reaching €1.44 billion, representing a 32% year-over-year increase compared to Q2 2024 ...